Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReal Est.cred Regulatory News (RECI)

Share Price Information for Real Est.cred (RECI)

Share Price is delayed by 15 minutes
Get Live Data
115.50    0.00 (0.00%)
Bid:
115.50
Ask:
116.00
Spread: 0.50 (0.433%)
Market Cap: £255.31m
RECI Live PriceLast checked at - London Stock Exchange

Intraday Real Est.cred Share Chart

Update re Financing Facility

28 Nov 2008 07:00

RNS Number : 1381J
Queen's Walk Investment Limited
28 November 2008
 



Update on QWIL's Financing Facility

As at 27 November 2008, the Company had drawn €40.5 million against its financing facility and had undrawn availability of €94.5 million. Given current market yields, the Company should be able to achieve its return objectives on new investments without the need for additional leverage. In addition, in today's highly volatile markets, the Company could have been exposed to material change clauses that might have triggered the requirement for the repayment of the facility on unfavourable terms.

In light of these circumstances, the Company has successfully negotiated amended terms on a reduced facility, involving a flexible two year repayment schedule of the outstanding debt and has reduced the risk associated with material change clauses that could have forced a repayment of the debt on unfavourable terms. The Company's cash balance of €16.5 million as at 27 November 2008 and continued cash flows from its investment portfolio support the repayment schedule and the timely redemption of the loan facility. The Company believes that the renegotiated loan facility is more prudent than continued dependence on an unpredictable lending market.

The Company has completed negotiations with its lender and the key elements of the amended facility are summarised below.

The Company has committed to repay the outstanding balance of the facility by October 2011, pursuant to an agreed loan amortisation schedule and will not make any further draw downs. The Company believes it should be able to satisfy the loan amortisation schedule with the €16.5 million of cash currently on the balance sheet and the expected cash flows from its investment portfolio. In addition, at the end of each quarter, the Company has pledged to keep the outstanding balance of the financing facility below the product of the then applicable advance rate ("Applicable Percentage") and the value of the investment portfolio plus cash (the "Borrowing Base"). At present, the Company's Borrowing Base is approximately €62.9 million versus a loan balance of €40.5 million

At the end of each calendar quarter, the Company has agreed a target loan amount ("Target Loan Amount") with the lenders. The Company has also agreed to an Applicable Percentage for every quarter. The Target Loan Amount and Applicable Percentage Schedule are detailed below:

Date

Target Loan Amount

Applicable Percentage for Residuals

31 December 2008

35,000,000

30%

31 March 2009 

33,000,000

30%

30 June 2009 

31,000,000

30%

30 September 2009

28,500,000

30%

31 December 2009

27,000,000

27.5%

31 March 2010 

25,000,000

20%

30 June 2010

12,000,000

20%

30 September 2010

10,000,000

20%

31 December 2010

0

20%

31 March 2011

0

10%

The Applicable Percentage for the Company's investment grade bond portfolio will be 50%, 40%, 30% and 15% for AA and above, A and above, BBB and above and BB and above; rated bonds respectively.

The Target Loan Amount will reduce by €11 million in the event that the Magellan 1 transaction is re-financed by the originator, BCP Millennium, before June 2010. The Applicable Percentage for residuals will reduce to 25% if the Magellan 1 transaction is re-financed by BCP Millennium before 31 December 2009.

The Company has committed to use a percentage of its Free Cash (cash proceeds in a quarter less dividends and operating expenses) to amortise the facility. Prior to the Magellan 1 transaction being refinanced, 75% of the Company's Free Cash will be used to repay the facility. After the Magellan 1 transaction is called, 66% of the Free Cash will be used to repay the debt. Once the outstanding balance of the facility is below €22 million, 50% of the Free Cash will be used to repay the facility. If the outstanding balance of the loan facility is less than the Target Loan Amount on the relevant date, the dividend will be capped at €2.25 million per quarter (or approximately a 19% dividend yield on the share price as at 26 November 2008). If the Company is unable to satisfy the loan amortisation schedule, the dividend will be capped at 8% on the share price prevailing at the end of each quarter. A failure to meet the loan amortisation schedule would not trigger an event of default.

In the event that the balance of the facility is greater than the Borrowing Base, the Company will have 20 business days to remedy the breach. Failure to remedy the breach would constitute an event of default. 

The Company has agreed to more asset specific tests in exchange for limiting the scope of the material change triggers and believes that the investment portfolio can support the amended facility.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZGMZMFNMGRZZ
Date   Source Headline
21st Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 202411:25 amEQSQ&A on Real Estate Credit Investments (RECI): Conservative accounting at play
13th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSFact Sheet Announcement
29th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20243:35 pmEQSHardman & Co Research on Real Estate Credit Investments (RECI): French and German exposures in perspective
22nd Feb 20244:25 pmRNSDividend Declaration
20th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20244:32 pmRNSDirector/PDMR Shareholding
8th Feb 20247:00 amRNSFact Sheet Announcement
5th Feb 20247:00 amRNSInvestment Manager's Q3 Investor Presentation
29th Jan 20247:00 amRNSTransaction in Own Shares
18th Jan 20245:57 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSTransaction in Own Shares
12th Jan 20241:54 pmRNSHolding(s) in Company
12th Jan 20247:00 amRNSFact Sheet Announcement
11th Dec 20237:00 amRNSFact Sheet Announcement
6th Dec 20237:00 amRNSTransaction in Own Shares
29th Nov 20237:00 amRNSDividend Declaration
29th Nov 20237:00 amRNSHalf-year Report
28th Nov 20231:30 pmEQSHadrman & Co Q&A on Q&A on Real Estate Credit Investments: Actively managing the portfolio to the latest market opportunities
16th Nov 202311:35 amEQSHardman & Co Research | Real Estate Credit Investments (RECI): Portfolio management to optimise risk/reward
9th Nov 20237:00 amRNSFact Sheet Announcement
3rd Nov 20237:05 amRNSInvestment Manager's Q2 Investor Presentation
25th Oct 20237:00 amRNSShare Buyback Programme in a Closed Period
18th Oct 20237:00 amRNSFact Sheet Announcement
15th Sep 20233:30 pmRNSResult of AGM
14th Sep 20234:11 pmRNSDividend Declaration
14th Sep 20237:00 amRNSFact Sheet Announcement
13th Sep 20233:45 pmEQSHardman & Co Q&A on Real Estate Credit Investments: Why commercial property worries do not apply to RECI
31st Aug 20237:00 amRNSShare Buyback Programme
30th Aug 20231:55 pmEQSHardman & Co Research on Real Estate Credit Investments (RECI): Why CRE equity worries should not apply to RECI
14th Aug 20237:00 amRNSFact Sheet Announcement
8th Aug 20237:00 amRNSInvestment Manager's Q1 Investor Presentation
20th Jul 20237:00 amRNSFact Sheet Announcement
13th Jul 20235:18 pmRNSDirector/PDMR Shareholding
13th Jul 202312:37 pmRNSDirector/PDMR Shareholding
6th Jul 20234:23 pmRNSDirector/PDMR Shareholding
6th Jul 20233:39 pmRNSDirector/PDMR Shareholding
6th Jul 20233:15 pmEQSHardman & Co Q&A on Real Estate Credit Investments (RECI): Stable dividends since 2013
22nd Jun 20237:00 amRNSDividend Declaration
22nd Jun 20237:00 amRNSAnnual Financial Report
13th Jun 202312:05 pmEQSHardman & Co Research on Real Estate Credit Investments (RECI): Double tangible security
13th Jun 20237:00 amRNSFact Sheet Announcement
18th May 20234:09 pmRNSDirector/PDMR Shareholding
12th May 20237:01 amRNSFact Sheet Announcement
12th May 20237:00 amRNSInvestment Manager's Q4 Investor Presentation
11th May 20233:33 pmRNSDirector/PDMR Shareholding
3rd May 20233:50 pmRNSDirector/PDMR Shareholding
14th Apr 20237:00 amRNSFact Sheet Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.